Abstract
Introduction. Medulloblastomas (MB) of the SHH group account for 25–30% of all MBs and are associated with aberrant activation of the intracellular SHH signaling pathway. The incidence of tumor predisposition syndromes (TPS) in patients with MB of the SHH group is about 20%, and this is the highest rate among the other molecular genetic subgroups of MB. In addition, there is significant molecular genetic heterogeneity within the same group, which in turn contributes to variations in survival rates and prognosis. Objective – to analyze the clinical, molecular, and genetic characteristics of TPS in patients with SHH group MB. Materials and methods. This retrospective study included a cohort of 40 patients aged 0 to 18 years with SHH group MB who underwent molecular genetic diagnostic testing between 2018 and 2024 at the D. Rogachev National Medical Research Center. The MB group was determined using NanoString technology. To identify germline mutations, DNA isolated from peripheral blood was examined using the following methods: next-generation sequencing, whole genome sequencing, Sanger sequencing, multiplex ligation-dependent probe amplification. The amplification of the MYC and NMYC genes was detected using fluorescence in situ hybridization. This study did not require approval from the local Ethics Committee, as the analyzed data did not contain any personalized information. Consent was obtained for the peripheral blood testing for TPS and for the publication of the data. Statistical processing and analysis of the data obtained were carried out using the R package version 4.4.2. Overall survival was estimated using the Kaplan–Meier method, and the cumulative incidence of secondary tumors was estimated using the competing risk method. To calculate the overall survival, we used the time from the date of diagnosis to death, and for the cumulative incidence of secondary tumors, we used the time from the date of diagnosis to the development of a secondary tumor, while death was considered a competing event. Results. Fifteen out of 40 patients were diagnosed with TPS. Gorlin syndrome was diagnosed in 7 people, Li–Fraumeni syndrome in 4 patients, there was one case each of Lynch syndrome and neurofibromatosis type 1, and a mutation in the ELP1 gene. One child had a combination of two syndromes (Gorlin and Lynch). The incidence of TPS in the analyzed cohort of 40 people was 37.5%. Thirteen people are alive, 2 patients died. The overall 4-year survival rate was 93% (the 95% confidence interval 82–100). A secondary tumor developed in 4 patients. The 4-year cumulative incidence of secondary tumors was 31% (the 95% confidence interval 6.4–61.0). All patients who developed a secondary tumor had received radiation therapy. Conclusion. When detecting MB of the SHH, it is important to conduct molecular genetic testing for TPS, given their high frequency among patients with MB of this molecular subgroup. The data obtained will help optimize therapy (avoid radiation therapy for young children with confirmed Gorlin syndrome), as well as predict the course of the disease. In addition, genetic testing is necessary for follow-up of such patients and for counseling their parents regarding the familial forms of the described syndromes.